Study #2021-0251
COGAALL1821: A phase 2 study of Blinatumomab (nsc# 765986, ind# 147294) in combination with Nivolumab (nsc #748726, ind# 147294), a checkpoint inhibitor of PD-1, in b-all patients aged ≥ 1 to < 31 years old with first relapse.
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Najat Daw Bitar
Department:
Pediatrics
For general questions about clinical trials:
1-866-720-1940
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.